Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Baxter of US to Begin New Global PIII Trial of Immunoglobulin for the Treatment of Alzheimer’s Disease
January 27, 2012
- Novartis Eyes Market Penetration with pNET Indication for Afinitor, Prolonged QOL for Patients
January 26, 2012
- Abbott Sets Up New Unit With MRs Specializing in CNS, Anesthetics for Luvox Transfer
January 26, 2012
- Nippon Kayaku’s Nambu Stresses Need for Collaboration between Medium-Sized Companies in Biosimilars
January 26, 2012
- Taiyo, Teva-Kowa to Establish Teva Pharma Japan in April, with 7 Branches, 29 Sales Offices Nationwide
January 26, 2012
- 301 MSs from Medipal HD Pass 18th MR Examination
January 26, 2012
- Achievement of SVR12 with DAA-only Combination Therapy Possible in Hepatitis C: BMS
January 26, 2012
- Toho HD Upwardly Revises FY2012 Earnings Forecast Expecting Boosted Sales, Profits
January 25, 2012
- Nichi-Iko, Sanofi to Jointly Develop Remicade Biosimilar
January 25, 2012
- Pfizer Japan Launches Zithromac for Intravenous Use
January 25, 2012
- CMIC HD to Merge 2 CRO Subsidiaries
January 25, 2012
- Mochida President Hopes to Ease Impact of Next NHI Price Revision with New Drugs
January 24, 2012
- Seikagaku Initiates PII Trial for SI-614 for Dry Eye in US
January 24, 2012
- Sosei Announces Collaboration with CEOLIA Pharma
January 24, 2012
- Wakamoto Pharmaceutical Withholds Joint Venture Plan with Major Taiwanese Generics Company
January 23, 2012
- Astellas to Transfer 3 Drugs to Choseido including Tathion
January 23, 2012
- Indications for Alveolar Pyorrhea Removed from Lysozyme HCl
January 23, 2012
- Growell President Takada Says Ready for Legal Action on Stoppage of “Dispensing Point” System
January 23, 2012
- NPhA’s Iwasaki Says Strength in Securing Profit Weak
January 23, 2012
- GSK Obtains Approval for Paxil CR Tablets, to Comarket with DSP
January 20, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…